Lutetium (177Lu) chloride 51.8 GBq/mL radiopharmaceutical precursor is revolutionizing targeted therapy and a game-changing theranostic isotope for treating neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC). PI Medical is the official distributor of this isotope in the Netherlands and Belgium, providing availability and ensuring improved quality of life and progression-free survival for patients with these indications.
Global Production and Supply: We meet demand on a global scale, ensuring that any required quantity is readily available.
Stable and Reliable Supply: Our supply chain is characterized by its stability, reliability, and punctuality. We guarantee on-time deliveries and provide guidance and support whenever necessary.
Compliance with Regulations: Our production process fully complies with cGMP regulations and adheres to the European Pharmacopeia's monograph, ensuring the highest quality standards.
Marketing Authorization: This product is authorized for marketing with the following Marketing Authorization numbers: EU/1/22/1680/001, EU/1/22/1680/002, EU/1/22/1680/003, EU/1/22/1680/004, EU/1/22/1680/005, EU/1/22/1680/006.
For more information on our Lutetium (177Lu) chloride 51.8 GBq/mL radiopharmaceutical precursor or to discuss your specific requirements, please contact us today. Our dedicated team is here to assist you and provide the support you need to advance your medical practice and improve patient outcomes.
